| | |  | | | | Record from Web of Science® | | | | | | |
| SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression |
|
|
| Author(s): Kent JM |
| Source: LANCET Volume: 355 Issue: 9207 Pages: 911-918 Published: MAR 11 2000 |
| Times Cited: 142 References: 80 |
| Abstract: A major goal of antidepressant development is to improve on preceding drug classes with agents with greater specificity (and therefore fewer unwanted side-effects) and with more rapid onset of antidepressant action. To this end, four antidepressants with significantly distinct pharmacological characteristics have been recently introduced: venlafaxine, nefazodone, mirtazapine, and reboxetine. Venlafaxine is the first antidepressant in a new drug class referred to as the serotonin noradrenergic reuptake inhibitors (SNaRIs). Nefazodone is a weaker serotonin and norepinephrine reuptake inhibitor, but a potent serotonin 5-HT2 receptor antagonist. Mirtazapine is a potent antagonist of central 2 alpha-adrenergic autoreceptors, and heteroreceptors and is an antagonist of serotonin 5-HT2 and 5-HT3 receptors. The result of these actions is to increase both noradrenergic and specific (5-HT1) serotonergic transmission, and mirtazapine has therefore been termed a noradrenergic and specific serotonergic antidepressant (NaSSA). Reboxetine is the first selective noradrenaline reuptake inhibitor (NaRI) to be introduced since the tricyclics, and lacks immediate serotonergic effects. |
| Document Type: Article |
| Language: English |
| Reprint Address: Kent, JM (reprint author), New York State Psychiat Inst, Unit 41, 1051 Riverside Dr, New York, NY 10032 USA |
Addresses:
1. New York State Psychiat Inst, Unit 41, New York, NY 10032 USA |
| Publisher: LANCET LTD, 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND |
| Subject Category: Medicine, General & Internal |
| IDS Number: 294DM |
| ISSN: 0140-6736 |
|
| | | | | | | | | Record from Web of Science® | | | | | | | | | |